Journal ArticleDOI
A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact
Siri Beier Jensen,Anne Marie Lynge Pedersen,Arjan Vissink,Elo Andersen,Carlton G. Brown,Andrew Davies,J. Dutilh,Janet S. Fulton,Ljiljana Janković,Nilza Nelly Fontana Lopes,A. L. S. Mello,L. V. Muniz,C. A. Murdoch-Kinch,Raj G. Nair,Joel J. Napeñas,A. Nogueira-Rodrigues,Deborah P. Saunders,B. Stirling,I. von Bültzingslöwen,Dianna Weikel,Linda S. Elting,Fred K. L. Spijkervet,Michael T. Brennan,Salivary Gland Hypofunction,Xerostomia Section +24 more
Reads0
Chats0
TLDR
There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment.Abstract:
This systematic review aimed to assess the literature for management strategies and economic impact of salivary gland hypofunction and xerostomia induced by cancer therapies and to determine the quality of evidence-based management recommendations. The electronic databases of MEDLINE/PubMed and EMBASE were searched for articles published in English since the 1989 NIH Development Consensus Conference on the Oral Complications of Cancer Therapies until 2008 inclusive. For each article, two independent reviewers extracted information regarding study design, study population, interventions, outcome measures, results, and conclusions. Seventy-two interventional studies met the inclusion criteria. In addition, 49 intensity-modulated radiation therapy (IMRT) studies were included as a management strategy aiming for less salivary gland damage. Management guideline recommendations were drawn up for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment. Management guideline recommendations are provided for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. Fields of sparse literature identified included effects of gustatory and masticatory stimulation, specific oral mucosal lubricant formulas, submandibular gland transfer, acupuncture, hyperbaric oxygen treatment, management strategies in pediatric cancer populations, and the economic consequences of salivary gland hypofunction and xerostomia.read more
Citations
More filters
Journal ArticleDOI
A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life
Siri Beier Jensen,Anne Marie Lynge Pedersen,Arjan Vissink,Elo Andersen,C. G. Brown,Andrew Davies,J. Dutilh,Janet S. Fulton,Ljiljana Janković,Nilza Nelly Fontana Lopes,A. L. S. Mello,L. V. Muniz,C. A. Murdoch-Kinch,Raj G. Nair,Joel J. Napeñas,A. Nogueira-Rodrigues,Deborah P. Saunders,B. Stirling,I. von Bültzingslöwen,Dianna Weikel,Linda S. Elting,Frederik Spijkervet,Michael T. Brennan +22 more
TL;DR: Salivary gland hypofunction and xerostomia are induced by radiotherapy in the head and neck region depending on the cumulative radiation dose to the gland tissue, and treatment focus should be on optimized/new approaches to further reduce the doses to the parotids.
Journal ArticleDOI
Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers
Arjan Vissink,James B. Mitchell,Bruce J. Baum,Kirsten H. Limesand,Siri Beier Jensen,Philip C. Fox,Linda S. Elting,Johannes A. Langendijk,Robert P. Coppes,Mary E. Reyland +9 more
TL;DR: This review addresses the pathophysiology underlying irradiation damage to salivary gland tissue, the consequences of radiation injury, and issues contributing to the clinical management of salivARY gland hypofunction and xerostomia.
Journal ArticleDOI
Interventions for the management of dry mouth: topical therapies.
TL;DR: There is no strong evidence from this review that any topical therapy is effective for relieving the symptom of dry mouth, and both integrated mouthcare systems and oral reservoir devices show promising results but there is insufficient evidence at present to recommend their use.
Journal ArticleDOI
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline
Noam Yarom,Noam Yarom,Charles L. Shapiro,Douglas E. Peterson,Catherine Van Poznak,Kari Bohlke,Salvatore L. Ruggiero,Salvatore L. Ruggiero,Cesar A. Migliorati,Aliya Khan,Archie Morrison,Archie Morrison,Holly Anderson,Barbara A. Murphy,Devena E. Alston-Johnson,Rui Amaral Mendes,Beth M. Beadle,Siri Beier Jensen,Deborah P. Saunders +18 more
TL;DR: In this paper, the authors provide guidance regarding best practices in the prevention and management of medication-related osteonecrosis of the jaw (MRONJ) in patients with cancer.
Journal ArticleDOI
Treatment of late sequelae after radiotherapy for head and neck cancer
Primož Strojan,Katherine A. Hutcheson,Avraham Eisbruch,Jonathan J. Beitler,Johannes A. Langendijk,Anne W.M. Lee,June Corry,William M. Mendenhall,Robert Smee,Alessandra Rinaldo,Alfio Ferlito +10 more
TL;DR: The available evidence on the use of different therapeutic strategies to alleviate common late sequelae of RT in head and neck cancer patients is reviewed, with a focus on the critical assessment of the treatment options for xerostomia, dysphagia, mandibular osteoradionecrosis, trismus, and hearing loss.
References
More filters
Journal ArticleDOI
Protective effect of amifostine on dental health after radiotherapy of the head and neck.
Volker Rudat,Jens Meyer,Felix Momm,Martin Bendel,Michael Henke,Vratislav Strnad,Knut A. Grötz,Andreas G. Schulte +7 more
TL;DR: The data suggest a protective effect of amifostine on the dental health after radiotherapy of the head and neck, and the dental status should be used as a primary endpoint in future studies on am ifostine.
Journal ArticleDOI
The effect of hyperbaric oxygen therapy on quality of life in oral and oropharyngeal cancer patients treated with radiotherapy.
TL;DR: Hyperbaric oxygen therapy (HBOT) may positively influence these long-term radiotherapy sequelae of xerostomia and related problems, and there was a reported subjective increase in saliva quantity and an improvement in sense of taste.
Journal ArticleDOI
Short-term radioprotective effects of WR-2721 on the rat parotid glands.
TL;DR: The radioprotective capacity of the chemoprotector WR-2721 was assessed in the rat parotid gland using gland weight and amylase content as the indicators of effect over the 9-day period following x irradiation with 1, 3, and 6.4 kR of acute x rays.
Journal ArticleDOI
A randomized phase III prospective trial of bethanechol to prevent radiotherapy-induced salivary gland damage in patients with head and neck cancer
Bruno Correia Jham,Inah Vanetti Teixeira,Clarissa Gonçalves Aboud,André Lopes Carvalho,Márcio M. Coelho,Addah Regina da Silva Freire +5 more
TL;DR: The use of bethanechol during RT for HNC cancer was associated with significantly higher WRS immediately after RT (p=0.03) in comparison to a similar cohort of patients who had not received bethaneschol.
Journal ArticleDOI
Prognostic factors in head-and-neck cancer patients treated with surgery followed by intensity-modulated radiotherapy (IMRT), 3D-conformal radiotherapy, or conventional radiotherapy.
Dirk Rades,Dirk Rades,Fabian Fehlauer,Junes Wroblesky,D. Albers,Steven E. Schild,Rainer Schmidt +6 more
TL;DR: Outcome was significantly associated with performance status, tumor stage, extent of resection, and pre-RT hemoglobin, and the three radiation techniques provided similar disease control.
Related Papers (5)
A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life
Siri Beier Jensen,Anne Marie Lynge Pedersen,Arjan Vissink,Elo Andersen,C. G. Brown,Andrew Davies,J. Dutilh,Janet S. Fulton,Ljiljana Janković,Nilza Nelly Fontana Lopes,A. L. S. Mello,L. V. Muniz,C. A. Murdoch-Kinch,Raj G. Nair,Joel J. Napeñas,A. Nogueira-Rodrigues,Deborah P. Saunders,B. Stirling,I. von Bültzingslöwen,Dianna Weikel,Linda S. Elting,Frederik Spijkervet,Michael T. Brennan +22 more
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Christopher M. Nutting,Christopher M. Nutting,James P Morden,Kevin J. Harrington,Kevin J. Harrington,Teresa Guerrero Urbano,Shreerang Bhide,Catharine H. Clark,Elizabeth Miles,Aisha Miah,Kate Newbold,Mary Anne Lagmay Tanay,Fawzi Adab,Sarah Jefferies,Christopher D Scrase,Beng K. Yap,Roger A'Hern,M. Sydenham,M. Emson,Emma Hall +19 more